Table 3.
Association of PA with the number of MSK pain locations
| No of MSK pain locations |
Dose of WHO guideline-based PA | |||||||||||
| 150–300 min | 300–450 min | 450–600 min | 600–750 min | 750–900 min | 900+ min | |||||||
| Crude OR (95% CI) |
Adjusted OR (95% CI) |
Crude OR (95% CI) |
Adjusted OR (95% CI) |
Crude OR (95% CI) |
Adjusted OR (95% CI) |
Crude OR (95% CI) |
Adjusted OR (95% CI) |
Crude OR (95% CI) |
Adjusted OR (95% CI) |
Crude OR (95% CI) |
Adjusted OR (95% CI) |
|
| Minimum one location |
1.06 (0.95 to 1.18) |
1.10 (0.98 to 1.23) |
1.04 (0.93 to 1.17) |
1.12 (0.99 to 1.27) |
1.01 (0.89 to 1.14) |
1.11 (0.98 to 1.26) |
0.92 (0.80 to 1.06) |
1.04 (0.90 to 1.20) |
1.09 (0.80 to 1.28) |
1.28 (1.10 to 1.51) |
1.05 (0.94 to 1.17) |
1.30 (1.16 to 1.45) |
| Minimum three locations |
0.89 (0.78 to 1.01) |
0.97 (0.85 to 1.11) |
0.80 (0.70 to 0.93) |
0.90 (0.78 to 1.04) |
0.80 (0.69 to 0.93) |
0.93 (0.80 to 1.08) |
0.86 (0.72 to 1.02) |
1.00 (0.84 to 1.19) |
0.93 (0.77 to 1.12) |
1.12 (0.93 to 1.36) |
0.88 (0.77 to 0.99) |
1.08 (0.94 to 1.23) |
| Minimum five locations |
0.76 (0.62 to 0.93) |
0.84 (0.69 to 1.03) |
0.65 (0.51 to 0.82) |
0.75 (0.60 to 0.95) |
0.61 (0.48 to 0.78) |
0.73 (0.57 to 0.93) |
0.74 (0.56 to 0.97) |
0.85 (0.64 to 1.13) |
0.87 (0.66 to 1.16) |
1.09 (0.82 to 1.45) |
0.83 (0.68 to 1.01) |
1.06 (0.87 to 1.29) |
| Minimum ten locations |
0.70 (0.45 to 1.07) |
0.76 (0.49 to 1.17) |
0.32 (0.17 to 0.61) |
0.36 (0.19 to 0.68) |
0.57 (0.34 to 0.98) |
0.64 (0.37 to 1.10) |
0.64 (0.35 to 1.19) |
0.67 (0.35 to 1.40) |
0.62 (0.31 to 1.23) |
0.70 (0.35 to 1.40) |
0.61 (0.39 to 0.95) |
0.67 (0.42 to 1.06) |
A group of participants who did not meet the WHO recommendations of PA (ie, PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status and depression risk. Significant OR's are marked bold.
MSK pain, musculoskeletal pain; PA, physical activity.;